Lipid metabolism after autologous orthotopic liver transplantation in rat models of fatty liver

doi:10.3969/j.issn.2095-4344.0560

Abstract

Abstract:

BACKGROUND: Incidence of primary non-function and early graft dysfunction after severe fatty liver transplantation is obviously increased. Therefore, it remains to be further studied to determine the extent to which the lipogenic properties can maximize the survival rate of grafts and receptors.
OBJECTIVE: To investigate the effect of autologous orthotopic liver transplantation on lipid metabolism in fatty liver rats.
METHODS: Totally 160 Sprague-Dawley rats were selected to establish moderate and severe fatty liver models through high-fat diet. Eighty rats were selected for each model. The rats with moderate and severe fatty liver were randomly divided into two subgroups, and then received orthotopic liver transplantation (groups A and B) or not (groups B and C). Liver function, lipid metabolism and liver histopathology were examined before surgery, 1 day, 1, 3 and 5 weeks after surgery.
RESULTS AND CONCLUSION: Liver function: in the group A, the levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase peaked at 1 day postoperatively, and then gradually decreased. The levels of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the group B at 5 weeks after surgery were higher than those in the group A (P < 0.05). Lipid metabolism: the postoperative total cholesterol, triacylglycerol and low-density lipoprotein levels in each group showed an overall downward trend, and the high-density lipoprotein and adiponectin levels showed an overall upward trend. At 5 weeks after surgery, the total cholesterol, triacylglycerol and low-density lipoprotein levels in the group A were significantly lower than those in the group B (P < 0.05), and the high-density lipoprotein and adiponectin levels were higher than those in the group B (P < 0.05). Liver histopathology: in the group A, the liver presented moderate steatosis at 1 day after surgery, and the degree of steatosis reversed at 5 weeks after surgery. In the group B, the liver presented severe steatosis at 1 day after surgery, and the liver presented moderate and severe steatosis at 5 weeks after surgery. No significant improvement was found, and there were infiltration of inflammatory cells, venous congestion in the manifold area and mild cholestasis. These results indicate that after autologous orthotopic liver transplantation, both middle and heavy fatty liver rats had different degrees of aggravation of lipid metabolism disorder. Compared with moderate fatty liver, heavy fatty liver can lead to more serious lipid metabolism disorder and slow recovery.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: Fatty Liver, Liver Transplantation, Reperfusion Injury, Adiponectin, Tissue Engineering

CLC Number:

R318

Ding Chen1, Jiang Yi2, Pan Fan2, Cai Qiucheng2. Lipid metabolism after autologous orthotopic liver transplantation in rat models of fatty liver [J]. Chinese Journal of Tissue Engineering Research, doi: 10.3969/j.issn.2095-4344.0560.

Figures/Tables 3

组内比较：A组术后1 d、1周的谷丙转氨酶、谷草转氨酶水平高于术前(P < 0.05)；B组术后1 d、1周、3周的谷丙转氨酶、谷草转氨酶水平高于术前(P < 0.05)；C、D组术后各时间点的谷丙转氨酶、谷草转氨酶水平无明显波动，提示自体肝移植后早期重度脂肪肝肝损害较中度脂肪肝重，且恢复慢。组间比较：与各自对照组比较，A组谷丙转氨酶和谷草转氨酶水平均于术后1 d、术后1周明显升高，B组谷丙转氨酶、谷草转氨酶水平均于术后1 d、术后1周、术后3周明显升高(P < 0.05)；与A组比较，B组术后的谷丙转氨酶和谷草转氨酶水平升高，提示自体肝移植对大鼠肝功能影响大，且肝移植对重度脂肪肝较中度脂肪肝肝损害严重。 2.2.2 血清总胆固醇、三酰甘油比较见图2，表2。4组大鼠总胆固醇和三酰甘油水平总体呈下降趋势。组内比较：A组术后1，3，5周的总胆固醇和术后3，5周的三酰甘油低于术前(P < 0.05)，B组术后1 d、1周的总胆固醇和术后1 d、1周、3周、5周的三酰甘油水平高于术前(P < 0.05)，C、D组术后总胆固醇和三酰甘油较术前稍下降或持平(P > 0.05)，提示重度脂肪肝大鼠自体肝移植后对总胆固醇和三酰甘油恢复产生较大影响。组间比较：与C组比较，A组术后3，5周的总胆固醇和三酰甘油水平下降缓慢(P < 0.05)；与D组比较，B组术后 1 d及3，5周的总胆固醇和三酰甘油水平下降缓慢(P < 0.05)；与A组比较，B组术后总胆固醇和三酰甘油水平下降明显变缓(P < 0.05)，提示自体肝移植对脂肪肝大鼠总胆固醇和三酰甘油产生影响，且对重度脂肪肝较中度脂肪肝影响大。 2.2.3 血清高密度脂蛋白、低密度脂蛋白比较见图3。4组高密度脂蛋白水平总体呈升高趋势，低密度脂蛋白水平呈下降趋势。组内比较：A、B组术后1 d、1周的高密度脂蛋白水平低于术前(P < 0.05)，C、D组术后3，5周的高密度脂蛋白水平高于术前(P < 0.05)；B组术后各时间点的低密度脂蛋白较术前无明显波动(P > 0.05)，A、C、D组术后1，3，5周的低密度脂蛋白水平低于术前(P < 0.05)。提示重度脂肪肝大鼠自体肝移植后高、低密度脂蛋白恢复不理想。"

组间比较：A、B组术后1 d、术后1周的高密度脂蛋白低于各自的对照组(P < 0.05)，且B组较A组更低(P < 0.05)；B组术后不同时间点的低密度脂蛋白高于D、A组(P < 0.05)，A组与C组相比差异无显著性意义(P > 0.05)。 2.2.4 血清脂联素总量比较见图4，显示了4组大鼠脂联素水平总体呈上升趋势。组内比较：A组术后1 d、1周、3周、5周的脂联素和B组术后1 d、1周、3周的脂联素水平均低于术前(P < 0.05)，C、D组术后1，3，5周的脂联素水平高于术前(P < 0.05)。提示行自体肝移植后，重度脂肪肝大鼠脂联素水平下降较中度脂肪肝大鼠显著且恢复慢。组间比较：A组术后1 d、1周、3周、5周的脂联素水平与C组比较差异显著(P < 0.05)，B组术后1 d、1周、3周脂的联素水平与D组比较差异显著(P < 0.05)，B组术后不同时间点的脂联素水平显著低于A组(P < 0.05)。 2.3 肝组织病理苏木精-伊红染色结果术前病理示，A、C组肝脏呈中度脂肪变性，肝细胞轻度气球样变性，汇管区结构基本正常；B、D组肝脏呈重度脂肪变性，肝细胞轻中度水样变性，肝细胞核向细胞边缘挤压，肝血窦受压变窄，汇管区结构尚可，见图5。 ①A组：术后1 d肝脏呈中度脂肪变性，肝细胞轻度肿胀伴水样变性，肝血窦轻度扩张，汇管区内见部分炎症细胞浸润，其余结构未见明显异常；术后5周呈轻度脂肪变性，肝细胞轻度肿胀，可见少量炎症细胞浸润，汇管区结构正常；②B组：术后1 d肝脏呈重度脂肪变性，肝细胞核向细胞边缘挤压，肝细胞肿胀伴水样变性，肝腺泡内见灶状坏死，肝血窦扩张，较多红细胞淤积。间质及汇管区见大量炎症细胞浸润，毛细胆管胆汁淤积；术后5周肝脏呈中重度脂肪变性，程度较前稍有好转，肝血窦轻度扩张，部分炎症细胞浸润，汇管区内静脉淤血及轻度胆汁淤积；③C组：术后1 d肝脏呈中度脂肪变性，轻度炎症细胞浸润，汇管区结构未见明显异常；术后5周肝脏呈轻度脂肪变性，未见炎症细胞浸润，其余结构正常；④D组：术后1 d肝脏呈重度脂肪变性，轻度炎症细胞浸润，汇管区血管扩张伴淤血，肝血窦轻微扩张伴红细胞淤积；术后5周肝脏呈轻中度脂肪变性，肝血窦未见明显红细胞淤积，汇管区未见血管扩张及炎性细胞浸润，结构未见明显异常，见图6。"

References

[1] Day CP. Non-alcoholic fatty liver disease: a massive problem. Clin Med. 2011;11(2):176-178.

[2] 白文元,李宁,白研.非酒精性脂肪性肝病诊治进展[J].胃肠病学, 2008, 12(12):713-716.

[3] DeAiwis NM, Day CP. Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-112.

[4] Devisscher L, Scott CL, Lefere S, et al. Non-alcoholic steatohepatitis induces transient changes within the liver macrophage pool. Cell Immunol. 2017;(322):74-83.

[5] Chackelevicius CM, Gambaro SE, Tiribel li C, et al. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World J Gastroenterol. 2016; 22(41):9096-9103.

[6] Lau JK, Zhang X, Yu J. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances. J Pathol. 2017; 241(1):36-44．

[7] Sadler EM, Mehta N, Bhat M, et al. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma. Transplantation. 2018;1(10):1.

[8] Andert A, Becker N, Ulmer F, et al. Liver transplantation and donor body mass index>30：use or refuse? Ann Transplant. 2016;21: 185-193．

[9] Croome KP, Lee DD, Keaveny AP, et al．Noneligible donors as a strategy to decrease the organ shortage. Am J Transplant. 2017;17(6): 1649-1655．

[10] Ploeg RJ, D'ALESSANDRO AM, Knechtle SJ, et al. Risk factors for primary dysfunction after liver transplantation-a multivariate analysis. Transplantation. 1993;55(4):807-813.

[11] 董玉茹,刘勉,马毅.探讨脂肪肝供肝在肝脏移植中的价值[J].中国CT和MRI杂志,2016,14(12):88-89.

[12] 付贞,明英姿,王彦峰,等.自体肝移植技术研究进展[J].中华肝胆外科杂志,2015,21(5):354-357.

[13] Dhir M, Lyden ER, Smith LM, et al. Comparison of outcomes of transplantation and resection in patients with early hepatocellular carcinoma: a meta-analysis. HPB (Oxford). 2012;14(9):635-645.

[14] Canter RJ, Patel SA, Kennedy T, et al. Comparative analysi of outcome inpatients with hepatocellular carcinoma exceedin the milan criteria treated with liver transplantation versus partial hepatectomy. Am J Clin Oncol. 2011;34(5):466-471.

[15] Jay C, Ladner D, Wang E, et al. A comprehensive risk assesment of mortality following donation after cardiac death liver transplantan analysis of the national registry. J Hepatol. 2011;55(4):808-813.

[16] Nakamura S, Suzuki S, Konno H, et al. Resection ofmetastatic liver tumors with special reference tohepatic venous system. Hepatogastroenterology. 1998;45(19):24-28.

[17] Li Y, Zhang PJ, Jin C, et al. Protective effects of deferoxamine mesylate preconditioning on pancreatic tissue in orthotopic liver autotransplantation inrats. Transplant Proc. 2011; 43(5): 1450-1455.

[18] Plock J, Frese S, Keogh A, et al. Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes inthe murine liver. J Hepatol. 2007; 47(4):538-545.

[19] Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34(3):274-285.

[20] Pascale A, Pais R, Ratziu V. An overview of nonalcoholic steatohepatitis: past, present and future directions. J Gastrointestin Liver Dis. 2010;19(4):415-423.

[21] Zhong Z, Lemasters JJ. Role of free radicals in failure of fatty liver grafts caused by ethanol. Alcohol. 2004;34(1):49-58.

[22] 梁绍勇.肝再生增强因子防治大鼠肝移植急性排斥反应实验研究[D].重庆:重庆医科大学,2008.

[23] Erridge C. Diet, commensals and the intestine as sources of pathogen-associated molecular patterns in atherosclerosis, type 2 diabetes and non-alcoholic fatty liver disease. Atherosclerosis. 2011; 216(1):1-6.

[24] 王少真,徐延光,史亚男.马来酸罗格列酮联合小剂量二甲双胍和那格列奈改善胰岛素抵抗对糖尿病前期伴非酒精性单纯性脂肪肝的逆转作用[J].中国全科医学,2009,12(5):729-731.

[25] Chavez-apia NC, Tiribelli C. Are non-invasive tests accurate enough to predict hepatic fibrosis in non-alcoholic fatty liver disease(NAFLD)Gut. 2008;57:1351-1353.

[26] Xi n YN, Xuan SY, Guan HS. Leptin: is it a possible specific liver drug for non-alcoholic fatty liver disease(NAFLD)．Med Hypot Heses. 2008; 71:462-463.

[27] 范建高.糖尿病与肝病的关系及其诊治对策[J].中华糖尿病杂志, 2009, 1(4):244-247.

[28] Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-1698.

[29] Pagano C, Soardo G, Esposito W, et al. Plasma adiponectin is decrease in nonalcoholic fatty liver disease. Eur J Endoerinol. 2005; 152:113-118.

[30] Ali R, Cnsi K. New diagnostic and treatment approaches in non-alcoho1ic fatty liver disease(NAFLD). Ann Med. 2009;41: 265-278.

[31] 皇甫竞坤,闫杰,王艳斌,等.血清脂联素水平与非酒精性脂肪性肝病相关性研究[J].中华临床医师杂志(电子版), 2013,7(7): 2852-2855.